Fortis Life Sciences, backed by Boston-based private equity firm Summit Partners, has acquired Toronto-based International Point of Care (IPOC).
IPOC specializes in developing and manufacturing diagnostic components. IPOC serves many of the leading global diagnostic companies enabling the commercialization of new immunodiagnostic and molecular diagnostic technologies.
Fortis Life Sciences partners with diagnostics and life sciences companies to custom-design, validate and manufacture proprietary solutions to solve their most difficult development problems. Fortis serves a global customer base and has offices worldwide including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America.
IPOC’s recently expanded 36,000-square-foot facility marks Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America. With this acquisition, Fortis hopes to provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. Financial terms of the deal were not disclosed.
The IPOC acquisition marks Fortis Life Sciences’ first deal of 2023. In March 2022, the company acquired Abcore, a leader in antibody discovery, for an undisclosed price.
